Compare FKWL & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FKWL | KLRS |
|---|---|---|
| Founded | 1981 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 46.0M |
| IPO Year | 1996 | N/A |
| Metric | FKWL | KLRS |
|---|---|---|
| Price | $4.14 | $8.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.00 | ★ $20.67 |
| AVG Volume (30 Days) | 14.0K | ★ 177.7K |
| Earning Date | 02-13-2026 | 11-12-2025 |
| Dividend Yield | ★ 0.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $45,508,949.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.05 | N/A |
| 52 Week Low | $3.67 | $2.14 |
| 52 Week High | $7.45 | $12.90 |
| Indicator | FKWL | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 54.06 |
| Support Level | $4.09 | $9.00 |
| Resistance Level | $4.42 | $9.45 |
| Average True Range (ATR) | 0.16 | 1.13 |
| MACD | -0.00 | -0.15 |
| Stochastic Oscillator | 27.51 | 23.79 |
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.